Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 September 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Advanced method for evaluation of gastric cancer risk by serum markers

This month's issue of Helicobacter reports on an advanced method for evaluation of gastric cancer risk by serum markers to determine true low-risk subjects for gastric neoplasm.

News image

Patients with negative anti-Helicobacter pylori antibody titer and high pepsinogen (PG) level (Group A) are regarded as having a low risk for gastric cancer.

However, gastric cancer cases are occasionally observed in this group.

Dr Masanori Ito and colleagues from Japan elucidated the clinical features of gastric neoplasm in Group A patients and reviewed advanced methods for mass screening.

A total of 271 gastric epithelial neoplasm patients were enrolled.

The research team classified them according to the Helicobacter pylori-pepsinogen system and determined the number of patients in each group.

After excluding trueHelicobacter pylori-negative cases from Group A, the team examined the differences between Group A and Group non-A.

Group A included 30 patients, and only 3 of these were true negative for Helicobacter pylori.

Histologically, 89% had little inflammation

Helicobacter

The team observed that all patients in Group A exhibited endoscopic atrophy in the gastric corpus.

Serologically, these patients showed low gastrin, low pepsinogen II and high pepsinogen I/II ratio, indicative of post-eradication.

Histologically, 89% of these had little inflammation, and 96% were negative for Helicobacter pylori by immunohistochemistry.

The team observed no difference in the incidence of metachronous gastric tumors between Group A and Group non-A.

The discriminant function using gastrin and pepsinogens could distinguish these 27 patients from true Helicobacter pylori-negative controls with 85% sensitivity and 84% specificity.

Dr Ito's team concludes, "Group A included a certain number of patients with atrophic gastritis who were potentially at risk of gastric neoplasm development."

"Although evaluation of corpus atrophy is necessary for the identification of these patients, the discriminant function may be useful."

Helicobacter 2014: 19(1): 1–8
19 February 2014

Go to top of page Email this page Email this page to a colleague

 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Technology vs intervention for weight loss
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Employment status and IBD
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Colorectal cancer survival and hospital volumes
 15 September 2016 
Primary sclerosing cholangitis and IBD
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 06 September 2016 
EHealth technologies in IBD
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Family history and IBD clinical course
 05 September 2016 
Biomarker for IBD and GI cancer
 02 September 2016 
Dietary carbohydrate intake, insulin resistance and GERD 
 02 September 2016 
Postpolypectomy bleeding in the colorectum
 02 September 2016 
Postop recurrence of Crohn's
 01 September 2016 
Prognostic test for liver transplants
 01 September 2016 
Recovery after colorectal surgery in elderly patients
 01 September 2016 
Obesity and post-ERCP pancreatitis
 30 August 2016 
NAFLD and carotid atherosclerosis
 30 August 2016 
Quality improvement program after colorectal surgery
 30 August 2016 
Gut microbial diversity in smokers with Crohn's
 29 August 2016 
Reducing Hep B-related HCC
 29 August 2016 
Hep B immunization of infants for liver cancer
 29 August 2016 
Risk factor for post-ERCP pancreatitis
 26 August 2016 
Reasons for premature surveillance colonoscopy
 26 August 2016 
Celiac disease therapeutics
 26 August 2016 
Bleeding after endoscopic dissection-induced gastric ulcers

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us